ATNX's oraxol has shown some pretty good data in metastatic breast cancer. And oral paclitaxel vs. IV paclitaxel seems to have some patient convenience advantage. However, the stock has not responded well to the oraxol metastatic breast cancer data readouts. The next step for ATNX for oraxol, is filing an NDA for FDA approval, after which as long as their submission is accepted, they will receive a PDUFA date. Will the stock respond with a nice pop upon a possible future FDA approval of oraxol in metastatic breast cancer based on its clinical data?
Read our deeper thoughts and competitive data comparison table in our Deeper Diligence section below: